-
Mashup Score: 9Targeting treatment resistance in chronic lymphocytic leukemia with a compound that goes beyond current BTK inhibitors - 3 month(s) ago
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help …
Source: medicalxpress.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0article - 7 month(s) ago
NewsOncology Times45(S10):p 3, May 20, 2023. | DOI: 10.1097/01.COT.0000936928.77325.9bChronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaAbout one-third of patients with advanced chronic lymphocytic leukemia (CLL) treated with the targeted drug ibrutinib do not carry two mutated genes commonly associated with relapse, according to an international study published in Blood Advances (2023;…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
About one-third of patients with advanced #ChronicLymphocyticLeukemia (CLL) treated with the targeted drug #ibrutinib do not carry two mutated genes commonly associated with #relapse, according to a study published in Blood Advances. https://t.co/HBLxoK0bCz #ThisIsBloodCancer https://t.co/u8e0YB3kJ1
-
-
Mashup Score: 1article - 8 month(s) ago
IntroductionChronic lymphocytic leukemia (CLL) is the most common type of leukemia affecting adults in western countries, mainly affecting older adults, with a median age at diagnosis of 72 years;1,2 its incidence and prevalence are expected to further increase in the short-term, proportionally increasing with the aging of the population.Chemo-immunotherapy regimens (eg, fludarabine…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Chemo-immunotherapy regimens have been the standard of care for #ChronicLymphocyticLeukemia. Yet, novel targeted agents—like #BTK and B-cell lymphoma-2 inhibitors—offer therapeutic options with higher #efficacy and personalized treatment. Learn more: https://t.co/BOKL4lNyrg #CLL https://t.co/2eC26XEqnd
-
-
Mashup Score: 0Future Potential of Noncovalent BTK Inhibitor Therapy for Patients With Chronic Lymphocytic Leukemia - 8 month(s) ago
Susan M. O’Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Here, Susan M. O'Brien, MD, discusses the possible applications of #pirtobrutinib, a noncovalent #BTK inhibitor, for the treatment of patients with #ChronicLymphocyticLeukemia #CLL. Learn more: https://t.co/wbtZQ7seC7 @UCIrvine https://t.co/ZGWob09x7Y
-
-
Mashup Score: 0Researchers Deliver Updates on Efforts Toward Eradicating CLL - 10 month(s) ago
Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Panelists at the @EHA_Hematology conference discuss current avenues being investigated to optimize the treatment of #ChronicLymphocyticLeukemia. Read more: https://t.co/VJpJGxVfgx https://t.co/lVXZ9KrgW4
-
-
Mashup Score: 2
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from…
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet-
Large-scale study of nine #genes in 4,580 patients with #chroniclymphocyticleukemia https://t.co/iV7DQjxAwV https://t.co/oY0gnRHesN
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zanubrutinib Shows Superior Efficacy With Fewer Side Effects Than Ibrutinib for #CLL: https://t.co/35b9bBMY4T #ChronicLymphocyticLeukemia #HemOnc https://t.co/5SDdJ2bts1
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zanubrutinib Shows Superior Efficacy With Fewer Side Effects Than Ibrutinib for #CLL: https://t.co/35b9bBMY4T #ChronicLymphocyticLeukemia #HemOnc https://t.co/AQMuXnOlfT
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zanubrutinib Shows Superior Efficacy With Fewer Side Effects Than Ibrutinib for #CLL: https://t.co/35b9bBMY4T #ChronicLymphocyticLeukemia #HemOnc https://t.co/MPymruVbjm
-
-
Mashup Score: 4Scientists map genetic evolution of chronic lymphocytic leukemia to Richter's syndrome - 1 year(s) ago
Every year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform into a far more aggressive cancer, a form of lymphoma known as Richter’s syndrome. For the most part, the genomic changes that underlie this metamorphosis and push it forward have been obscure, hindering advances in treatment.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Scientists map genetic evolution of #chroniclymphocyticleukemia to Richter's syndrome @danafarber @NatureMedicine https://t.co/hAIF2jRctI
-
Targeting treatment resistance in #chronicLymphocyticLeukemia with a compound that goes beyond current BTK inhibitors @umiamimedicine @sciencemagazine https://t.co/7ntugJdB6w